Therapy-induced subtypes of recurrent PC are also inherently resistant to hormone ablation [21], Neuroendocrine prostate cancer (NEPC) is classically insensitive to most conventional therapies which target the androgen receptors [22]. The gene discussed is AR; the disease is pachyonychia congenita.